MLT-231

• CAT Number: I045442
• CAS Number: 2682102-10-7
• Molecular Formula: C19H19ClF3N7O2
• Molecular Weight: 469.85
• Purity: ≥95%
• Synonyms: 1-[2-chloro-7-[(3S,5S)-3,5-dimethylmorpholin-4-yl]pyrazolo[1,5-a]pyrimidin-6-yl]-3-[2-(trifluoromethyl)pyridin-4-yl]urea
• InChI: InChI=1S/C19H19ClF3N7O2/c1-10-8-32-9-11(2)29(10)17-13(7-25-16-6-15(20)28-30(16)17)27-18(31)26-12-3-4-24-14(5-12)19(21,22)23/h3-7,10-11H,8-9H2,1-2H3,(H2,24,26,27,31)/t10-,11-/m0/s1
• InChIKey: BFPCFGGFGQMJQG-QWRGUYRKSA-N
• SMILES: CC1COCC(N1C2=C(C=NC3=CC(=NN32)Cl)NC(=O)NC4=CC(=NC=C4)C(F)(F)F)C

MLT-231 (Cat No.: I045442) is a potent, selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1), an enzyme that catalyzes the aberrant conversion of α-ketoglutarate to the oncometabolite D-2-hydroxyglutarate (2-HG) in certain cancers. By blocking mutant IDH1 activity, MLT-231 reduces 2-HG accumulation, restoring normal epigenetic regulation and promoting cellular differentiation. It is primarily investigated for the treatment of IDH1-mutant malignancies, including gliomas and acute myeloid leukemia (AML), and serves as a valuable tool for studying metabolic and epigenetic reprogramming in cancer biology.

Reference

[1]. Pissot Soldermann C, et al. Discovery of Potent, Highly Selective, and In Vivo Efficacious, Allosteric MALT1 Inhibitors by Iterative Scaffold Morphing [published online ahead of print, 2020 Nov 30]. J Med Chem. 2020;10.1021/acs.jmedchem.0c01245.
[Content Brief]